Renicus S. Hermanides

3.8k total citations · 2 hit papers
45 papers, 986 citations indexed

About

Renicus S. Hermanides is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Renicus S. Hermanides has authored 45 papers receiving a total of 986 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Cardiology and Cardiovascular Medicine, 23 papers in Surgery and 10 papers in Internal Medicine. Recurrent topics in Renicus S. Hermanides's work include Acute Myocardial Infarction Research (31 papers), Antiplatelet Therapy and Cardiovascular Diseases (20 papers) and Coronary Interventions and Diagnostics (20 papers). Renicus S. Hermanides is often cited by papers focused on Acute Myocardial Infarction Research (31 papers), Antiplatelet Therapy and Cardiovascular Diseases (20 papers) and Coronary Interventions and Diagnostics (20 papers). Renicus S. Hermanides collaborates with scholars based in Netherlands, Italy and Germany. Renicus S. Hermanides's co-authors include Arnoud W.J. van ‘t Hof, Jean‐Paul R. Herrman, Jurriën M. ten Berg, Willem J.M. Dewilde, Emanuele Barbato, Pim van der Harst, Folkert W. Asselbergs, Vera H.M. Deneer, Gerrit J.A. Vos and Thomas O. Bergmeijer and has published in prestigious journals such as New England Journal of Medicine, The American Journal of Cardiology and American Heart Journal.

In The Last Decade

Renicus S. Hermanides

43 papers receiving 967 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI

2019 378 citations Daniel M.F. Claassens, Gerrit J.A. Vos et al. New England Journal of Medicine profile →
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction

2022 243 citations Jean‐Paul R. Herrman, Renicus S. Hermanides et al. profile →

Peers

Countries citing papers authored by Renicus S. Hermanides

Since Specialization

Citations

This map shows the geographic impact of Renicus S. Hermanides's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renicus S. Hermanides with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renicus S. Hermanides more than expected).

Fields of papers citing papers by Renicus S. Hermanides

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renicus S. Hermanides. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renicus S. Hermanides. The network helps show where Renicus S. Hermanides may publish in the future.

Co-authorship network of co-authors of Renicus S. Hermanides

This figure shows the co-authorship network connecting the top 25 collaborators of Renicus S. Hermanides. A scholar is included among the top collaborators of Renicus S. Hermanides based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renicus S. Hermanides. Renicus S. Hermanides is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Increased incidence of adverse events in diabetes mellitus patients with combined multiple vulnerable plaque features: new insights from the COMBINE OCT-FFR trial 2024 ·European Heart Journal - Cardiovascular Imaging ·David del Val, Balázs Berta, Tomasz Roleder, Krzysztof Piotr Malinowski, Teresa Bastante, Renicus S. Hermanides, Wojciech Wojakowski, Enrico Fabris, Javier Cuesta, Giuseppe De Luca, Fernando Rivero, F Alfonso, Elvin Kedhi	0
2	ULTrasound-guided TRAnsfemoral puncture in COmplex Large bORe PCI: study protocol of the UltraCOLOR trial 2022 ·BMJ Open ·T Meijers, Alexander Nap, Adel Aminian, Joseph Dens, Koen Teeuwen, Jan‐Peter van Kuijk, Marleen van Wely, Thomas Schmitz, Yoann Bataille, Adriaan O. Kraaijeveld, Vincent Roolvink, Renicus S. Hermanides, Thijs L. Braber, Niels van Royen, (unknown)	6
3	Prehospital treatment with zalunfiban (RUC-4) in patients with ST‐ elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial 2022 ·American Heart Journal ·(unknown), (unknown), Renicus S. Hermanides, Barry S. Coller, C. Michael Gibson, Christopher B. Granger, Frédéric Lapostolle, Sonja Postma, (unknown), (unknown), Gilles Montalescot, Jurriën M. ten Berg, Arnoud W.J. van ‘t Hof	10
4	Unraveling the Multitude of Etiologies in Myocardial Infarction With Nonobstructive Coronary Arteries 2022 ·The American Journal of Cardiology ·(unknown), (unknown), Renicus S. Hermanides, Saman Rasoul, Jan Paul Ottervanger, Arnoud W.J. van ‘t Hof	1
5	Efficacy and safety of glycoproteinIIb/IIIainhibitors in addition toP2Y₁₂inhibitors inST‐segment elevation myocardial infarction: A subanalysis of thePOPularGenetics trial 2021 ·Catheterization and Cardiovascular Interventions ·(unknown), Daniel M.F. Claassens, Renicus S. Hermanides, Gerrit J.A. Vos, Thomas O. Bergmeijer, Johannes C. Kelder, Vera H.M. Deneer, Arnoud W.J. van ‘t Hof, Jurriën M. ten Berg	4
6	Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype 2021 ·Circulation Cardiovascular Interventions ·Daniel M.F. Claassens, Thomas O. Bergmeijer, Gerrit J.A. Vos, Renicus S. Hermanides, Arnoud W.J. van ‘t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, (unknown), Folkert W. Asselbergs, Arend Mosterd, Jean‐Paul R. Herrman, Willem J.M. Dewilde, Paul W.A. Janssen, Johannes C. Kelder, Bakhtawar K. Mahmoodi, Vera H.M. Deneer, Jurriën M. ten Berg	17
7	Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial 2021 ·American Journal of Cardiovascular Drugs ·Daniel M.F. Claassens, (unknown), Gerrit J.A. Vos, Thomas O. Bergmeijer, Renicus S. Hermanides, Arnoud W.J. van ‘t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, (unknown), Folkert W. Asselbergs, Arend Mosterd, Jean‐Paul R. Herrman, Willem J.M. Dewilde, Maarten J. Postma, Vera H.M. Deneer, Jurriën M. ten Berg, Cornelis Boersma	16
8	Sex Differences in Platelet Reactivity in Patients With ST-Elevation Myocardial Infarction: A Sub-Analysis of the ON-TIME 3 Trial 2021 ·Frontiers in Cardiovascular Medicine ·(unknown), Renicus S. Hermanides, Jan Paul Ottervanger, Svetlana V. Belitser, Olaf H. Klungel, Yolande Appelman, (unknown), Arnoud W.J. van ‘t Hof	3
9	Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI 2020 ·International Journal of Cardiology ·(unknown), Renicus S. Hermanides, Enrico Fabris, Dominick J. Angiolillo, Arnoud W.J. van ‘t Hof	8
10	Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS 2020 ·Cardiovascular Diabetology ·(unknown), Renicus S. Hermanides, Balázs Berta, Enrico Fabris, Giuseppe De Luca, Eline H. Ploumen, Clemens von Birgelen, Elvin Kedhi	1
11	Complex Large-Bore Radial percutaneous coronary intervention: rationale of the COLOR trial study protocol 2020 ·BMJ Open ·T Meijers, Adel Aminian, Koen Teeuwen, Marleen van Wely, Thomas Schmitz, Maurits T. Dirksen, René J. van der Schaaf, Juan F. Iglesias, Pierfrancesco Agostoni, Joseph Dens, Paul Knaapen, Sudhir Rathore, Jan Paul Ottervanger, Jan‐Henk E. Dambrink, Vincent Roolvink, A.T. Marcel Gosselink, Renicus S. Hermanides, Niels van Royen, (unknown)	4
12	Duration of dual antiplatelet therapy after myocardial infarction: Insights from a pooled database of the SMART-DATE and DAPT-STEMI trials 2020 ·Atherosclerosis ·Elvin Kedhi, Ronak Delewi, Enrico Fabris, Giuseppe De Luca, Renicus S. Hermanides, (unknown), Paweł Buszman, Felix Zijlstra, Young Bin Song, Hyeon‐Cheol Gwon, Joo‐Yong Hahn	3
13	A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI breakdown → 2019 ·New England Journal of Medicine ·Daniel M.F. Claassens, Gerrit J.A. Vos, Thomas O. Bergmeijer, Renicus S. Hermanides, Arnoud W.J. van ‘t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, (unknown), Folkert W. Asselbergs, Arend Mosterd, Jean‐Paul R. Herrman, Willem J.M. Dewilde, Paul W.A. Janssen, Johannes C. Kelder, Maarten J. Postma, Anthonius de Boer, Cornelis Boersma, Vera H.M. Deneer, Jurriën M. ten Berg	378
14	Optimal pharmacological therapy in ST-elevation myocardial infarction—a review 2018 ·Netherlands Heart Journal ·Renicus S. Hermanides, (unknown), Arnoud W.J. van ‘t Hof	8
15	Factors associated with deferred lesion failure following fractional flow reserve assessment in patients with diabetes mellitus 2017 ·Catheterization and Cardiovascular Interventions ·Mark Kennedy, Enrico Fabris, Renicus S. Hermanides, E. Kaplan, (unknown), Balázs Berta, Petra C. Koopmans, Jan Paul Ottervanger, Harry Suryapranata, Elvin Kedhi	10
16	Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. 2012 ·PubMed ·Renicus S. Hermanides, Jan Paul Ottervanger, Jurriën M. ten Berg, A.T. Marcel Gosselink, Gert van Houwelingen, Jan‐Henk E. Dambrink, Pieter R. Stella, Christian W. Hamm, Arnoud W.J. van ‘t Hof	6
17	The Impact of Age on Effects of Pre-hospital Initiation of High Bolus Dose of Tirofiban Before Primary Angioplasty for ST-Elevation Myocardial Infarction 2011 ·Cardiovascular Drugs and Therapy ·(unknown), Renicus S. Hermanides, Gert van Houwelingen, Jan Paul Ottervanger, Menko‐Jan de Boer, Thorsten Dill, Christian W. Hamm, Pieter R. Stella, Eric Boersma, Jurriën M. ten Berg, Arnoud W.J. van ‘t Hof	2
18	Suboptimal anticoagulation with pre-hospital heparin in ST-elevation myocardial infarction 2011 ·Thrombosis and Haemostasis ·Renicus S. Hermanides, Jan–Henk Dambrink, M. J. de Boer, (unknown), (unknown), Harry Suryapranata, (unknown), Arnoud W.J. van ‘t Hof, Jan Paul Ottervanger, (unknown)	5
19	High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial 2010 ·Heart ·Renicus S. Hermanides, Antonius A.C.M. Heestermans, Jurriën M. ten Berg, A.T. Marcel Gosselink, Jan Paul Ottervanger, K. Gert van Houwelingen, Jeroen J. Kolkman, Pieter R. Stella, Thorsten Dill, Christian W. Hamm, Arnoud W.J. van ‘t Hof	8
20	Risk of bleeding after prehospital administration of high dose tirofiban for ST Elevation Myocardial Infarction 2010 ·International Journal of Cardiology ·Renicus S. Hermanides, Jan Paul Ottervanger, Jan‐Henk E. Dambrink, Thorsten Dill, Gert van Houwelingen, Jurriën M. ten Berg, Evelien Kolkman, Christian W. Hamm, Arnoud W.J. van ‘t Hof	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact